Clinical Trial

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

Study acronym: PEAK
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-17; most recent amendment 2026-05-14.
Status change: Not Yet Recruiting → Recruiting 2025-09-03
Trial Details
NCT Number NCT06990399
Lead Sponsor Kodiak Sciences Inc
Conditions Macular Edema Secondary to Inflammation
Enrollment 600 participants
Start Date 2025-07-30
Primary Completion 2027-04 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-18